Diagnostic Radioisotopes Market, By Radioisotope (Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, Others ), By Application (Diagnostic Application and Therapeutic Application), By Imaging Modality (SPECT, PET, Beta Emitters), By Disease Indication (Oncology, Cardiology, Neurology, Thyroid, Orthopedic, Endocrinology, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Nov 2023

Code : CMI6190

Pages :145

Formats :

Excel and PDF

Industry : Medical Devices

Diagnostic Radioisotopes MarketSize and Trends

Global diagnostic radioisotopes market size is expected to reach US$ 10.36 Bn by 2030, from US$ 5.67 Bn in 2023, at a CAGR of 9% during the forecast period. Diagnostic radioisotopes are radioactive elements that are used for medical imaging to diagnose various diseases like cancer, cardiovascular diseases, neurological disorders etc. these help in early and accurate disease diagnosis. Global diagnostic radioisotopes market is segmented by radioisotope, application, imaging modality, end user, indication and region. By radioisotope, the market is segmented into Technetium-99m, Thallium-201, Gallium-67 and others. Technetium-99m is the largest segment due to its wide usage in nuclear medicine diagnostics.

Global Diagnostic Radioisotopes Market- Trends

Shift Towards Value-based Care: The shift towards value-based care and bundled payments in healthcare increases need for accurate diagnostics like nuclear imaging with radioisotopes. This supports the market growth.
Growing Use of Artificial Intelligence: The integration of artificial intelligence in medical imaging like PET and SPECT scans improve workflow efficiency. Companies are actively developing AI-based imaging solutions.
Advancements in Radiochemistry: The advancements in radiochemistry and automated radiosynthesis methods help to efficiently produce high-quality radioisotopes. This enhances safety and productivity.
Increasing Use of Radiohybrid Imaging: The use of hybrid imaging systems combining functional modalities like PET/MRI, SPECT/CT is rising. This improves diagnostic accuracy and supports radioisotope adoption.

Global Diagnostic Radioisotopes Market- Recent Developments

New Product Launches & Approval

On July 28, 2023, Curium, a leader in nuclear medicine, announced that the European Commission had granted marketing authorization for PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL) that is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa)
On February 2, 2023, RefleXion Medical, a therapeutic oncology company, announced that the U.S. Food and Drug Administration (FDA) had granted the first marketing clearance for its SCINTIX biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers
On May 27, 2021, Lantheus Holdings, Inc., a leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) had approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer.